Therapy Areas: Inflammatory Diseases
Zoetis introduces Portela for feline osteoarthritis pain relief in Canada and EU
22 July 2026 - Animal health company Zoetis Inc (NYSE: ZTS) announced on Wednesday that it has launched Portela (relfovetmab) in Canada and European Union member states, introducing the first long-act...
Arch Biopartners engages private lab to advance IL-32 chronic kidney disease programme
20 July 2026 - Canada-based biotechnology company Arch Biopartners Inc (TSX-V:ARCH) (OTCQB:ACHFF) announced on Friday that it has engaged a US-based laboratory specialising in bioengineering to accele...
Vanda Pharmaceuticals reports positive EMA opinion on orphan drug designation for imsidolimab in generalised pustular psoriasis
17 July 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Thursday that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopt...
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
16 July 2026 - Biotechnology company Valerio Therapeutics (Euronext Growth Paris:ALVIO) on Thursday announced a binding term sheet with Abivax for an exclusive global research and development collabor...
Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis
15 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage drug development company focused on immune and inflammatory diseases, announced on Tuesday the completion of patient enrolment in the Phase...
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
13 July 2026 - Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Monday that it has received marketing authorisation in Sweden for Tofacitinib Newbury 5 mg and 10 mg ...